Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) EBIT: 2009-2024

Historic EBIT for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to -$22.6 million.

  • Ligand Pharmaceuticals' EBIT rose 1647.73% to $54.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year increase of 207.32%. This contributed to the annual value of -$22.6 million for FY2024, which is 289.30% down from last year.
  • Ligand Pharmaceuticals' EBIT amounted to -$22.6 million in FY2024, which was down 289.30% from $11.9 million recorded in FY2023.
  • In the past 5 years, Ligand Pharmaceuticals' EBIT ranged from a high of $103.9 million in FY2021 and a low of -$22.6 million during FY2024.
  • Moreover, its 3-year median value for EBIT was $3.0 million (2022), whereas its average is -$2.5 million.
  • Per our database at Business Quant, Ligand Pharmaceuticals' EBIT skyrocketed by 293.22% in 2023 and then crashed by 289.30% in 2024.
  • Ligand Pharmaceuticals' EBIT (Yearly) stood at $37.5 million in 2020, then soared by 176.94% to $103.9 million in 2021, then tumbled by 97.08% to $3.0 million in 2022, then skyrocketed by 293.22% to $11.9 million in 2023, then plummeted by 289.30% to -$22.6 million in 2024.